Telix Pharmaceuticals Limited (TLPPF)
USD 15.71
(0.0%)
USD 15.71
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 17.44 Million AUD | 67.0% |
| 2022 | 10.44 Million AUD | 311.42% |
| 2021 | 2.53 Million AUD | 15.04% |
| 2020 | 2.2 Million AUD | 3.57% |
| 2019 | 2.13 Million AUD | 23.23% |
| 2018 | 1.72 Million AUD | 400.6% |
| 2017 | 345.43 Thousand AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 19.08 Million AUD | -28.67% |
| 2024 Q2 | 11.85 Million AUD | 77.94% |
| 2023 Q4 | 17.44 Million AUD | 3.53% |
| 2023 Q1 | 12.69 Million AUD | 21.49% |
| 2023 Q2 | 13.1 Million AUD | 3.25% |
| 2023 Q3 | 16.85 Million AUD | 28.6% |
| 2023 FY | 17.44 Million AUD | 67.0% |
| 2022 Q4 | 10.44 Million AUD | 6.54% |
| 2022 Q2 | 2.56 Million AUD | 27.6% |
| 2022 Q3 | 9.8 Million AUD | 282.11% |
| 2022 Q1 | 2.01 Million AUD | -20.8% |
| 2022 FY | 10.44 Million AUD | 311.42% |
| 2021 Q3 | 1.92 Million AUD | 13.56% |
| 2021 Q4 | 2.53 Million AUD | 31.83% |
| 2021 Q2 | 1.69 Million AUD | 42.88% |
| 2021 Q1 | 1.18 Million AUD | -46.22% |
| 2021 FY | 2.53 Million AUD | 15.04% |
| 2020 Q3 | 1.7 Million AUD | -44.59% |
| 2020 Q1 | 1.59 Million AUD | -25.34% |
| 2020 Q4 | 2.2 Million AUD | 29.52% |
| 2020 FY | 2.2 Million AUD | 3.57% |
| 2020 Q2 | 3.07 Million AUD | 93.27% |
| 2019 FY | 2.13 Million AUD | 23.23% |
| 2019 Q1 | 1.7 Million AUD | -1.42% |
| 2019 Q2 | 1.8 Million AUD | 5.85% |
| 2019 Q4 | 2.13 Million AUD | 1.0% |
| 2019 Q3 | 2.11 Million AUD | 16.93% |
| 2018 Q1 | 364.68 Thousand AUD | 5.57% |
| 2018 FY | 1.72 Million AUD | 400.6% |
| 2018 Q4 | 1.72 Million AUD | 0.01% |
| 2018 Q3 | 1.72 Million AUD | 374.11% |
| 2018 Q2 | 364.68 Thousand AUD | 0.0% |
| 2017 FY | 345.43 Thousand AUD | 0.0% |
| 2017 Q2 | - AUD | 0.0% |
| 2017 Q3 | 345.43 Thousand AUD | 0.0% |
| 2017 Q4 | 345.43 Thousand AUD | 0.0% |
| 2017 Q1 | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 57.661% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -323.221% |
| SQZ Biotechnologies Company | 27.47 Million USD | 36.497% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 59.779% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 41.395% |
| Mesoblast Limited | 118.7 Million USD | 85.303% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -1739.664% |
| Genus plc | 233.1 Million USD | 92.516% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -495.314% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1198.393% |
| Marizyme, Inc. | 18.71 Million USD | 6.798% |
| ContraFect Corporation | 2.88 Million USD | -505.519% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -2226.0% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -12775.774% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -1106.165% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -650.015% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -208.305% |
| MultiCell Technologies, Inc. | 202.58 USD | -8611312.775% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 69.655% |
| EV Biologics, Inc. | 1.49 Million USD | -1067.084% |
| Q BioMed Inc. | 4.1 Million USD | -324.455% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 47.298% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -2668.709% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -1320.185% |
| Biomind Labs Inc. | 735.54 Thousand USD | -2271.72% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 89.831% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -34.223% |
| Skye Bioscience, Inc. | 4.61 Million USD | -277.985% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -1864.385% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -12227.054% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -197.134% |
| IMV Inc. | 28.88 Million USD | 39.603% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -67729.231% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -672.456% |
| GB Sciences, Inc. | 1.75 Million USD | -891.584% |
| Alpha Cognition Inc. | 1.22 Million USD | -1329.482% |
| HST Global, Inc. | 98.31 Thousand USD | -17643.264% |
| CSL Limited | 12.18 Billion USD | 99.857% |
| Halberd Corporation | 150 Thousand USD | -11530.0% |
| Enzolytics Inc. | 996.33 Thousand USD | -1650.912% |
| Resverlogix Corp. | 6.49 Million USD | -168.757% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -3553.403% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -6725.331% |
| argenx SE | 20 Million USD | 12.775% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 61.71% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -544.035% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -170511.247% |
| Genscript Biotech Corporation | 417.73 Million USD | 95.824% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -8595.717% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -627.565% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -7508.236% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 74.21% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -476.467% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -4749.74% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 14.182% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -11635.305% |
| BioStem Technologies, Inc. | 4.71 Million USD | -270.271% |
| ONE Bio Corp. | 19.71 Million USD | 11.514% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -6872.924% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -6913.911% |
| Agentix Corp. | 50 Thousand USD | -34790.0% |
| LadRx Corporation | 33.6 Thousand USD | -51810.373% |
| Cell Source, Inc. | 9.25 Million USD | -88.51% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -2206.917% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -2206.917% |
| NovAccess Global Inc. | 2.19 Million USD | -692.998% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -146.649% |
| Itoco Inc. | 228.37 Thousand USD | -7538.685% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -8168.752% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -250.09% |
| Kadimastem Ltd | 891.22 Thousand USD | -1857.416% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -4241.183% |
| CytoDyn Inc. | 30.07 Million USD | 41.997% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -3502.225% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -4858.121% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -123.083% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -14140.816% |
| Rebus Holdings, Inc. | 310 Thousand USD | -5527.419% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -268.405% |
| International Stem Cell Corporation | 4.17 Million USD | -317.544% |
| Bioxytran, Inc. | 1.92 Million USD | -806.234% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -27850.908% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -699.899% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -109.776% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -103.203% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -1021.519% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -6409.328% |
| Neutra Corp. | 54.15 Thousand USD | -32112.497% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -853.279% |
| PureTech Health plc | 25.51 Million USD | 31.62% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -1324.982% |
| IXICO plc | 472.02 Thousand USD | -3595.794% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -12.541% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 71.982% |
| CSL Limited | 12.18 Billion USD | 99.857% |
| Cellectis S.A. | 92.77 Million USD | 81.197% |